Jan 9 (Reuters) - The U.S. Environmental Protection Agency will reassess the safety of herbicide paraquat, its administrator Lee Zeldin said on Friday on X, adding that the body is requiring manufacturers to thoroughly prove that current uses are safe in real-world conditions.
Syngenta, which markets paraquat under the brand name Gramoxone, is among the herbicide's major sellers.
The Swiss-based agricultural chemical company is facing several lawsuits in the U.S., where plaintiffs allege exposure to paraquat caused them to develop Parkinson's, a degenerative brain disease that leads to loss of muscle coordination.
It has previously said there was "no credible evidence" that paraquat causes Parkinson's.
In agricultural settings, paraquat is mostly applied to soybean, corn and cotton crop fields to control invasive weeds and grasses, according to the Environmental Protection Agency.
(Reporting by Costas Pitas and Pooja Menon; Editing by Alan Barona)
LATEST POSTS
- 1
Treasure trove found in Egyptian tomb solves ancient mystery - 2Why are malnutrition deaths soaring in America?
- 3BravoCon 2025: How to watch, full schedule and lineup, where to stream free and more
- 4Foreign military officials can become Israel's ambassadors, senior IDF commander tells 'Post'
- 5As tetanus vaccination rates decline, doctors worry about rising case numbers
- Step by step instructions to Choose the Right Internet based Degree Program for Your Future
- U.S. to drop childhood vaccine recommendations as it looks to Denmark, Washington Post reports
- Volcanic eruption led to the Black Death, new research suggests
- The Main 15 Powerful Business Heads of Today
- Change Your Skincare: 10 Inventive Magnificence Gadgets
- The Electric Toyota Hilux Is Finally here, But It's Not Cheap
- If evolution is real, then why isn’t it happening now? An anthropologist explains that humans actually are still evolving
- It Shouldn’t Be Here: Rescuers Race to Save Whale Stranded in Rare Spot
- UK clothing inflation climbs as Middle East turmoil threatens wider price rises
